People · Operator
Named in public records as an officer, director or promoter · active 2020–2021 · Pharmaceuticals
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| BlossomHill Therapeutics, Inc. | — | Pharmaceuticals | Series C | $245.8M | $452.7M | 2020 |
Li Peter Yishan at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Li Peter Yishan on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Carl Gordon | 1 | 24 |
| BIHUA CHEN | 1 | 14 |
| George Lee | 1 | 6 |
| Yishan Li | 1 | 4 |
| Hongbo Lu | 1 | 4 |
| JINGRONG JEAN CUI | 1 | 2 |
| TIMOTHY STUBBS | 1 | 1 |
| SUNDEEP AGRAWAL | 1 | 1 |
| George Peter Lee | 1 | 1 |
| Bihua Peter Chen | 1 | 1 |
| Carl Peter Gordon | 1 | 1 |
| Jingrong Peter Jean Cui | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.